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Abstract
Background: In intensive care unit (ICU), infection and colonization by resistant Gram-negative bacteria increase
costs, length of stay and mortality. Extended-spectrum beta-lactamase − producing Enterobacteriaceae (ESBL-E) is a
group of pathogens increasingly encountered in ICU setting. Conditions that promote ESBL-E acquisition are not
completely understood. The increasing incidence of infections related to ESBL-E and the unsolved issues related to
ESBL-E cross-transmission, prompted us to assess the rates of referred and acquired cases of ESBL-E in ICU and to
assess patient-to-patient cross-transmission of ESBL-E using a multimodal microbiological analysis.
Methods: During a 5-month period, all patients admitted to a medical ICU were tested for ESBL-E carriage. A rectal
swab was performed at admission and then twice a week until discharge or death. ESBL-E strains were analyzed
according to antibiotic susceptibility pattern, rep-PCR (repetitive-element Polymerase chain reaction) chromosomal
analysis, and plasmid PCR (Polymerase chain reaction) analysis of ESBL genes. Patient-to-patient transmission was
deemed likely when 2 identical strains were found in 2 patients hospitalized simultaneously in the ICU.
Results: Among the 309 patients assessed for ESBL-E carriage on admission, 25 were found to carry ESBL-E
(importation rate: 8 %). During follow-up, acquisition was observed among 19 of them (acquisition rate:
6.5 %). Using the multimodal microbiological approach, we found only one case of likely patient-to-patient
ESBL-E transmission.
Conclusions: In unselected ICU patients, we found rather low rates of ESBL-E referred and acquired cases.
Only 5 % of acquisitions appeared to be related to patient-to-patient transmission. These data highlight
the importance of jointly analyzing phenotypic profile and molecular data to discriminate strains of ESBL-E.
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Background
In intensive care unit (ICU), Gram-negative bacterial
resistance to antibiotic therapy increases costs, length of
stay and mortality [1, 2]. One major mechanism of
resistance is related to extended-spectrum beta-lactamase
(ESBL) production. Since the first report in mid-1980s,
the incidence of ESBL-producing Enterobacteriaceae
(ESBL-E) has been increasing worldwide [3]. “Old” ESBL
(derived from SHV and TEM families) were, until the
year 2000, essentially related to Klebsiella pneumoniae
and Escherichia coli, which were responsible for noso-
comial infections, mostly in the ICU setting [4, 5].
Escherichia coli thereafter became dominant among
ESBL-E. Interestingly, the change of dominant species
occurred concomitantly with the emergence of en-
zymes that belong to the CTX-M family. These “new”
ESBL have superseded the TEM- and SHV-related
enzymes, and their incidence is currently increasing
in the community setting [6, 7].
ESBL-E community carriage and/or hospital acquisi-
tion rates vary worldwide. In Madagascar, more than
10 % of healthy volunteers carry an ESBL-E strain [8]. In
Spain, ESBL-E carriage increases between 1991 and 2003
of 1–5 % among ambulatory patients and 1–12 % among
hospitalized patients [9]. In France, carriage of ESBL-E is
about 1 % in healthy volunteers [10] and up to 6 % in
patients admitted to a medical ward [11].
Acquisition can be due to transmission from one
patient to another via health care worker’s hands. This
pattern is largely accepted for glycopeptide-resistant
Enterococcus (GRE), and prevention programs de-
signed to minimize cross-transmission, have reduced
this mode of acquisition [12–15]. Programs designed
to prevent the spread of “old” ESBLs are less convin-
cing and even discordant with “new” ESBLs epidemi-
ology [16, 17]. Other patterns of acquisition include
antibiotic pressure [18], and the use of antibiotics in
food animal breeding [19]. Regarding the environ-
ment, some authors report possible GRE and Methicilin
Resistant Staphylococcus aureus (MRSA) contamination
from bedroom furniture and medical devices [20, 21],
which can be decreased by reinforced environmental
cleaning [22].
The relative contributions of all these factors to ESBL-
E acquisition are incompletely understood [23]. Contact
isolation measures are usually applied to ESBL-E carriers
[14] but are potentially harmful for patients and their
effectiveness is even debated [24].
The increasing incidence of infections related to
community-acquired or nosocomial ESBL-E and the is-
sues raised by data on patient-to-patient transmission,
prompted us to assess colonization and acquisition rates
of ESBL-E and to characterize ESBL-E cross-transmission
using microbiological multimodal analysis.
Methods
Study design and patient population
This study was approved by the Comité de Protection
des Personnes de l’Hôpital Saint-Antoine.
We assessed in a multimodal analysis, microbiological
samples collected during routine screening for multidrug-
resistant bacteria in the medical ICU of a 660-bed tertiary
teaching hospital, during a period of 5 consecutive months
(March 15th to August 15th, 2011). The medical ICU has 3
units containing each 6 single beds. Two physicians are in
charge of a Unit. A nurse cares for 3 patients. All patients
admitted to the medical ICU were given information on
the study and their (or next of kin) oral consent was
obtained. Every patient underwent rectal swab screen-
ing for ESBL-E carriage at admission and then twice
a week until ICU discharge. Enhanced hygiene mea-
sures (protective gowns, gloves, ESBL-E announcing
stickers) were applied in the case of patients colo-
nized and/or infected by ESBL-E and preventively in
patients considered at risk for ESBL-E carriage.
Microbiological methods
Screening for ESBL-E was performed by inoculating rec-
tal swabs on selective medium supplemented with cef-
tazidime (bioMérieux, Marcy l’Etoile, France). After 24 h
at 37 °C, the species were identified by MALDI-TOF
(Matrix-Assisted Laser Desorption/Ionisation, time-of-
flight mass spectrometry) analysis. Antibiotic susceptibil-
ity was tested using the standard agar diffusion method
on Mueller-Hinton agar (Bio-Rad, Marnes-la-Coquette,
France) according to CA-SFM 2012 guidelines. The
following antibiotics (bioRad) were tested: amoxicillin,
amoxicillin-clavulanate, ticarcillin, piperacillin, piperacillin-
tazobactam, cefalotine, cefoxitine, moxalactam, cefotaxime,
ceftazidime, aztreonam, cefepime, imipenem, ertapenem,
meropenem, gentamicin, tobramycin, netilmicin amikacin,
nalidixic acid, ofloxacin, ciprofloxacin and sulfamethoxa-
zole. The double-disk synergy method was used to confirm
ESBL production [25]. All ESBL-E − producing isolates
were stored at −80 °C.
Molecular methods
Clonal relationships of ESBL-E isolates were investigated
using the DiversiLab® fingerprinting system (bioMérieux,
Marcy l'Etoile, France), a commercially available repetitive-
element (rep)-PCR tool [26] successfully used for the typing
of ESLB-E. This technique is faster than and as discriminat-
ing as pulsed-field gel electrophoresis [27, 28]. After thaw-
ing, strains were isolated and incubated at 37 ° C for 24 h.
DNA was extracted using an UltraClean DNA isolation kit®
(MO-BIO, USA). The DNA solutions were then normal-
ized at a concentration of 35 ng/mL. For the study, we used
specific rep-PCR kits respectively for Escherichia coli,
Enterobacter ssp., and Klebsiella spp. species. PCR cycling
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parameters for all the kits were similar: an initial denatur-
ation at 94 °C for 2 min, 35 cycles of denaturation at 94 °C
for 30 s, hybridization (at 55 °C for Enterobacter spp. and
Klebsiella spp. and at 50 °C for Escherichia coli) for 30 s,
extension at 70 °C for 90 s and a final extension at 70 °C
for 3 min. DNA amplicons were separated by a bioanalyzer
(Agilent Technologies, Les Ulis, France).
DiversiLab® software was used for analysis of the
results. This used the Pearson correlation coefficient to
determine distance matrices and the UPGMA method
(Unweighted Pair Group Method with Arithmetic Mean)
to create dendrograms. Reports were automatically gen-
erated including dendrogram, electropherogram, virtual
gel images and scatter plots to aid in data interpretation.
A cluster was defined by a set of strains having both a
similarity coefficient equal to or greater than 95 % and
difference less than 2 peaks on the electropherogram.
In order to complement the results, all ESBL genes
were characterized. DNA preparation and multiplex
PCRs, previously developed to detect the most frequent
widespread beta-lactamase genes encoding the ESBL
(SHV-, TEM- and CTX-M-types), were performed as
previously described [29]. PCR products were purified
using the ExoSap purification kit (Illustra EXOSTAR-1
Step, Duscher, Brumath, France). All PCR products
were subjected to bidirectional DNA sequencing using
the BigDye terminator 3.1 cycle sequencing kit (Applied
Biosystems, Foster City, CA, USA). Each sequence was
aligned using Applied Biosystems SeqScape® software. The
nucleotide sequences and deduced protein sequences were
analyzed with the BLAST and FASTA programs of the
National Centre for Biotechnology Information.
Definitions
According to the results of culture and clinical data
(date of admission and discharge, location and transfer
within the unit, and previous admissions), each ESBL-
producing strain was classified as referred or acquired in
the unit. Referred cases were those that met any of the
following criteria: patient with ESBL-producing strain
found at admission; patient with ESBL-producing strain
found from a clinical sample within 48 h following ICU
admission; and/or history of colonization and/or infec-
tion with an ESBL-producing strain (defined by positive
rectal swab and/or positive microbiologic exam for
ESBL-E at a previous stay). The rate of referred cases
was computed for patients who underwent sampling at
admission. ESBL-E acquired cases were defined by the
identification 72 h after admission of one ESBL-E strain
among patients with negative admission screening. Iden-
tification of several novel ESBL-E strains with different
beta-lactamases at the same sampling was considered as
several acquisitions. Acquisition rate was computed for
patients in whom admission sampling had been per-
formed. ESBL-E acquired cases occurring among
patients carrying referred strains was defined as identifi-
cation 72 h after admission and during follow-up of an
ESBL-E strain different from the one identified on ad-
mission sampling. Cross-transmission (patient-to-patient
transmission) was recorded when strains isolated among
2 patients were similar in both beta-lactamase gene
characterization and rep-PCR analysis. Moreover, the 2
patients ICU stays had to overlap.
Statistics
Quantitative values were expressed as the median
with the interquartile range [25–75 %]. Rates for re-
ferred cases and acquired cases were calculated con-
sidering only patients whose screening samples at
admission were available. For identification of cross-
transmission, all ESBL-E strains isolated during the
study were considered and acquisitions were studied,
one by one, on the basis of antibiotic susceptibility
pattern, ESBL-type rep PCR profile, and the patient’s
period of ICU stay. The Mann–Whitney test was used
to compare quantitative values. Proportions were




During the 5-month study period, 432 patients were
admitted to the medical ICU (age 64 years [51–76],
male/female ratio 56 %, IGSII 38 [27–52]) (Table 1).
Table 1 Demographic data
Patients without positive ESBL-E sample ESBL-E referred patients ESBL-E acquired patients p
Number 268 25 19
Age (years) 63 [51–75] 65 [59–76] 67 [49–78] 0.39 a0.52 b
Sex ratio (M/F) 57 48 68 0.40 a0.35 b
IGS 2 38 [27–51] 42 [33–47] 42 [36–51] 0.55 a0.39 b
ICU Mortality (%) 19 16 15.7 1 a1 b
Length of stay (days) 4 [3–6] 7 [6–9] 12 [8–23] <0.005a<0.005 b
(Age, IGS 2 and length of stay are expressed as medians, acomparison between ESBL-E imported patients and patients without positive ESBL-E cultures,
bcomparison between ESBL-E acquired patients and patients without positive ESBL-E cultures)
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They were mainly admitted for medical reasons (90 %):
respiratory failure (54 %), septic shock (21 %), coma
(14 %), postoperative major surgery (5 %), and others
pathologies (6 %). Patients came from a medical ward
(54 %), from surgery (5 %), and from home (41 %).
Length of stay was 5 days [3–7], and mortality was 18 %.
ESBL-E referred cases/acquired cases (Fig. 1)
Patients
On admission, rectal swabs were performed in 309/432
patients (72 %). Twenty-five were positive for ESBL-E
(referred cases rate 8 %) with 25 strains isolated from 25
patients. During follow-up of these 309 patients, 20
acquisitions were observed with 20 strains isolated from
19 patients (acquired cases: 6.5 %). Acquisition was
observed in 3/19 of patients known to carry an
ESBL-E upon admission. Acquisition occurred after
7 days [4–15] and ICU length of stay was significantly
higher in patients who acquired ESBL-E (12 vs. 4 days,
p < 0.005). Twelve patients had a history of
colonization related in their records. For six of them,
an ESBL-E was identified on a rectal swab during
ICU stay. Among the 123 patients for whom admis-
sion samples were not available (and who therefore
were not taken into account in computing rates of
imported cases at admission and acquired cases), sub-
sequent follow-up revealed carriage of ESBL-E strains
in 10 of them.
Strains
Fifty-two ESBL-producing strains of Enterobacteriaceae
including E. coli (n = 27), E. cloacae (n = 11), K. pneumo-
niae (n = 10), and K. oxytoca (n = 4) were isolated during
the study.
Phenotypic analysis
Phenotypic classification of the strains was based on Anti-
biotic susceptibility profile defined as: I: gentamicin- and
amikacin-sensitive; II: gentamicin-resistant and amikacin-
sensitive; III: gentamicin-sensitive and amikacin-resistant;
a: ciprofloxacin-sensitive; b: ciprofloxacin-resistant. This
allowed discriminating 5 different antibiotic resistance
patterns for E. coli, 4 for E. cloacae, 5 for K. pneumoniae,
and 2 for K. oxytoca (Additional file 1).
Molecular analysis
Molecular typing derived from rep-PCR analysis discrimi-
nated several clusters respectively among E coli, E cloacae,
K pneumoniae, K oxytoca isolates.
Fig. 1 Flow chart
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– For the 27 E. coli isolates, (Fig. 2), 17 clusters were
individualized: 13 of them with a single isolate,
whereas clusters 6, 7, 9 and 14 contained
respectively 3, 2, 2, and 7 isolates.
– For E. cloacae, (Fig. 3); molecular typing
discriminated 7 clusters: 5 clusters each
containing only one isolate, one cluster
with 2 isolates, and one cluster observed
with 4 isolates.
– Three of the 10 K. pneumoniae isolates were
part of the same cluster whereas each
remaining seven were from a different
cluster (Fig. 4).
– The 4 K. oxytoca isolates each showed a distinct
cluster (Fig. 5).
Our results showed CTX-M enzymes to be the most
frequent ESBL-types (Additional file 1). ESBL for E. coli
included 21 CTX-M (8 CTX-M-15, 7 CTX-M-1, 1 CTX-
M-3, and 5 CTX-M-14), 2 TEM-type enzymes and 2
SHV-12. For Klebsiella species, 8/10 K. pneumoniae pro-
duced CTX-M-15 whereas the 4 K. oxytoca produced
SHV-12. Finally, 10/11 E. cloacae were CTX-M-15
producers.
Integrating all molecular results has allowed showing
that in the same cluster, analysis of the genes encoding
ESBL resistance is required to differentiate strains there
between. For example, on E. coli, cluster 14 contains 1
strain with resistance encoded by CTX-M-27, 5
strains with resistance encoded by CTX-M-15, and 1
strain with resistance encoded by CTX-M-14). More-
over, we observed strains of the same species with
similar resistance profiles that did not derive from the
same cluster (Additional file 1).
Cross-transmission
Eleven ESBL-E acquisitions out of 19 (19 patients) corre-
sponded to an ESBL-E that was found neither on hy-
giene sampling nor on clinical sampling performed
during the study period, which makes patient-to-patient
transmission very unlikely.
One patient acquired an E. coli strain, which
belonged to a cluster, found on admission sampling
in another patient admitted to our ICU 10 days after.
Whereas they belonged to the same cluster, these 2
strains exhibited both a different pattern of antibiotic
susceptibility to aminoglycosides and a different ESBL
type.
An E. cloacae acquisition was observed in one pa-
tient, 13 days before the admission of another patient
to the same unit from whom admission screening
samples indicated the same strain (Cluster 7), making
patient-to-patient cross-transmission very unlikely.
Four ESBL-Es were acquired during the study
period (similar cluster and ESBL analysis) in the same
unit (one E. coli (Cluster 14), 2 E. cloacae (Cluster 6),
one K. pneumoniae (Cluster 1). However, there was
no overlap in the ICU stays of these patients, suggest-
ing that patient-to-patient transmission was very
unlikely.
E. coli (E18) was found in follow-up sampling in one
patient (acquisition). This cluster (14) was found in
samples from another (E22) patient. However, molecular
analysis individualized 2 different ESBL-types (CTX-M-27
and CTX-M-15).
Fig. 2 Dendrogram analysis and virtual gel images of DiversiLab
rep-PCR fingerprinting system (bioMérieux) for the 27 E. coli
isolates
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Finally, according to molecular (rep PCR and ESBL
PCR) and phenotypic typing and bearing in mind
geographic and temporal compatibility, only one
case of highly probable patient-to-patient transmis-
sion occurred during the study (K. pneumoniae,
Cluster 1).
Discussion
In this study, we assessed the rates of referred ESBL-E at
admission and ESBL-E acquisition during ICU stay. Our
study complements the few ones that have investigated
Enterobacteriaceae acquisition and cross-transmission
using a multimodal approach [16, 17, 30].
Fig. 3 Dendrogram analysis and virtual gel images of DiversiLab rep-PCR fingerprinting system (bioMérieux) for the 11 E. cloacae isolates
Fig. 4 Dendrogram analysis and virtual gel images of DiversiLab rep-PCR fingerprinting system (bioMérieux) for the 10 K. pneumoniae isolates
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In our study, ESBL-E carriage at admission and acqui-
sition during ICU stay were rare, occurring in 8 % and
6 % of patients, respectively. Using phenotypic and
molecular typing, and considering geographic and tem-
poral compatibility, we observed only one possible case
of patient-to-patient transmission among the 19 patients
who acquired an ESBL-E during their ICU stay.
ESBL-E imported cases accounted for less than 10 %
in the ICU. This rate is in keeping with data published
during the last decade. In 2007, Buke et al. reported at
admission ESBL-E carriage in less than 8 % of patients
who stayed for more than a month in a French hospital
[31]. In Spain, carriage of ESBL-E among hospitalized
patients was 8.2 % in 2010 [32]. The acquisition rate was
6 % in the present study. Despite recently observed
emergence of community-acquired ESBL-E, in-hospital
ESBL-E acquisition remained stable over years. This
could suggest that either hygiene measures are effective
or that the role attributed to patient-to-patient transmis-
sion of ESBL-E in the acquisition pattern is weak [3]. In
the present study, using a multimodal microbiological
approach, the observed acquisition rate was very low.
Indeed, among 309 patients screened on admission to
the ICU, cross-transmission was considered likely in
only one patient. This result is certainly due to many
issues. First, the present study was conducted during a
period of very low endemicity. In consequence, we
cannot exclude the possibility that different results may
be observed during a period of high endemicity or
during an outbreak. In addition, isolation measures ap-
plied in a preventive manner could have modified the
cross-transmission rate [33].
A recently published study using a similar method-
ology reported possible patient-to-patient transmission
for only 3 patients in 69 cases of ESBL-E acquisition
[34]. In an older French study, cross-transmission rate
was higher with over 85 % of strains acquired, but this
study was only based on antibiotic susceptibility [35].
We compared both phenotypic analysis, based on anti-
biotic susceptibility, and molecular analysis. We con-
firmed that the capacity of antibiotic susceptibility
analysis to discriminate similar strains is weak. More-
over, we confirm that strain with similar antibiotic
susceptibility patterns and which belong to the same
cluster (relying on rep-PCR) can differ only by their
ESBL production. This is the case for 2 pairs of E. coli
isolates (18 and 22) and (12 and 13) that carried (CTX-
M 27 and CTX-M 15) and (SHV 12 and CTX-M 14),
respectively. These observations are consistent with the
fact that ESBL genetic support is mainly extrachromo-
somal (plasmid-related). As reported by several other
authors, we observed this phenomenon only for E. coli
strains [16, 17]. Our data highlight the importance-
combined analysis of phenotypic profile and molecular
data to discriminate ESBL-E strains.
The present study, however, has several limitations.
First, despite its worldwide use, the rectal swab is of
limited sensitivity in detecting ESBL-E carriage. This
issue is well documented for vancomycin-resistant
enterococci (VRE), for which probability of detection
is inversely proportional to the number of colony-
forming units in rectal swabs [36]. The risk of false-
negative results with rectal swabs is probably lower
for ESBL-E due to the virulence and larger inocula
observed with these bacteria [23]. However, Harris et
al. reported a non-detection rate of 69 % for E. coli
and Klebsiella spp. [37]. In the present study, when
rectal swabs were considered by laboratory techni-
cians as containing insufficient amount of stool, they
were discarded and rectal sampling was immediately
re performed.
Antimicrobial exposure could have contributed to
change duration of carriage and limited the detection
during the study. Among patients with at least one
positive rectal swab, 48 % had successively several
negative rectal swabs. For 66 % of them, active antibi-
otics on isolated ESBL-E were administered when
negative screening samples were observed. Duration
of colonization by the ESBL-E strain is difficult to as-
sess. One study showed that the median duration of
carriage of ESBL-producing Klebsiella pneumoniae
was 160 days after hospital discharge [38]. This study
Fig. 5 Dendrogram analysis and virtual gel images of DiversiLab rep-PCR fingerprinting system (bioMérieux) for the 4 K. oxytoca isolates
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showed a significant variability between patients.
Haverkate et al. showed that the median duration of
carriage of highly resistant ESBL Enterobacteriaceae
was 1.4 months in patients colonised with a MDRO
during a previous stay in the ICU [39]. Currently,
there is no formal data to recommend routine screen-
ing to assess the persistence of carriage.
Second, potential increased risk of acquisition, trans-
mission and carriage which antimicrobial may contribute
exposure was not looked for.
Third, sampling at admission was analysable in only
70 % of patients. The pertinence of the carriage rate we
observed would have been probably greater with a
higher percentage of patients sampled on admission.
However, we included 86 % of all patients in the cross-
transmission analysis, a percentage similar to that in
most studies designed to characterize multiresistant
strains cross-transmission.
Median length of stay was short (4 days), which is
usual length of stay of patients admitted to our unit.
However, we observed that patients who acquired ESBL-
E had a significantly longer ICU stay (12 days). A similar
study in patients who spend longer in the ICU may,
therefore, indicate a different acquisition rate. Further-
more, criteria as those used to define cross-transmission
can be appropriate for an ICU with short median lengths
of stay but are not necessarily applicable in other ICU
settings.
Finally, it should be highlighted that patient-to-
patient transmission was low in our study. This can
be related to several issues. Protective isolation mea-
sures were applied as soon as ESBL-E detection and
immediately at admission in patients at high risk of
carrying ESBL-E. In several cases of acquisition,
patient-to-patient transmission initially deeming likely
(because the strains were identical) was finally ruled
out because there was no overlap of patient ICU
stays. This type of acquisition could account for a
possible acquisition from inanimate surfaces since
ESBL-E can survive in such conditions for a long
time [21].
Conclusions
In this observational study conducted in patients with a
relatively short length of stay in the ICU, low rates of
both ESBL-E carriage at admission and ESBL-E acquisi-
tion during ICU stay were observed. Using a multimodal
microbiological approach, we identified only one pos-
sible case of patient-to-patient transmission of ESBL-
E among the 19 acquisitions observed during ICU
stay. These data highlight the importance of jointly
analyzing phenotypic and molecular profiles, to dis-
criminate strains of ESBL-E before assuming that they
are identical.
Additional file
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